|
CureVac
CureVac N.V. is a German biopharmaceutical company that develops therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. The company's focus is on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Curevac In Tübingen 02
CureVac N.V. is a German biopharmaceutical company that develops Nucleoside-modified messenger RNA, therapies based on messenger RNA (mRNA). Legally domiciled in the Netherlands and headquartered in Tübingen, Tübingen, Germany, the company was founded in 2000 by Ingmar Hoerr (CEO), Steve Pascolo (CSO), Florian von der Mulbe (COO), Günther Jung, and Hans-Georg Rammensee. CureVac had approximately 240 employees in November 2015 and 375 in May 2018. At the beginning of the COVID-19 pandemic, CureVac was considered a beacon of hope for the development of a German vaccine. The Fourth Merkel cabinet, federal government invested 300 million euros in the company. First, the CureVac vaccine was delayed due to minor problems, while the previously unknown BioNTech developed with Pfizer the very effective Pfizer–BioNTech COVID-19 vaccine, BNT162b2. In mid-2021, however, it became clear that the CureVac-vaccine was only 47 percent effective and is far away from approval. The company's ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Ingmar Hoerr
Ingmar Malte Hoerr (born 1968 in Neckarsulm) is a German biologist. He pioneered vaccinology research concerning the use of RNA and is a founder of the German biotechnology company CureVac. He created the initial technology used in RNA vaccines and has reportedly been nominated for a Nobel Prize. He is currently an Ambassador for the European Innovation Council for the years 2021–2027. Early life and education Hoerr graduated from the Johannes-Kepler-Realschule in Wendlingen am Neckar in 1985 and then attended an agricultural high school in Nürtingen, where he obtained his Abitur in 1988. From 1988 to 1990, he performed civilian service at the DRK Nürtingen as a paramedic. From 1990 to 1996 he studied biology at the University of Tübingen. During his studies, he spent a year at Madurai Kamaraj University, India. Career Career in academia Hoerr did experimental research on the stabilization of messenger ribonucleic acid (mRNA). In 1999, he received his PhD from Günt ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Günther Jung
Günther Jung (born 2 September 1937 in Tübingen) is a German chemist. He was professor for Organic Chemistry and Biochemistry at the University of Tübingen from 1973 to 2002. Career Günther Jung studied chemistry at the University of Tübingen and after his diploma thesis in 1965 he received his PhD in 1967. From 1967 to 1968 he was assistant professor at the University of Houston in Texas (USA). In 1971 he was granted permission to teach organic chemistry and biochemistry at the University of Tübingen, where he held a permanent university professorship from 1973 to 2002. His successor in the department of organic chemistry is Stephanie Grond.https://uni-tuebingsoren/prof-dr-stephanie-grond/ G. Jung has been in the advisory committee of eight scientific journals and on the boards of several institutions. He was also research consultant in the pharmaceutical industry and organized many international symposia and workshops. Until 1996 he was also director of the biochemist ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Coalition For Epidemic Preparedness Innovations
The Coalition for Epidemic Preparedness Innovations (CEPI) is a foundation that takes donations from public, private, philanthropic, and civil society organisations, to finance independent research projects to develop vaccines against emerging infectious diseases (EID). CEPI is focused on the World Health Organization's (WHO) " blueprint priority diseases", which include: the Middle East respiratory syndrome-related coronavirus (MERS-CoV), the Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the Nipah virus, the Lassa fever virus, and the Rift Valley fever virus, as well as the Chikungunya virus and the hypothetical, unknown pathogen " Disease X". CEPI investment also requires "equitable access" to the vaccines during outbreaks, although subsequent CEPI policy changes may have compromised this criterion. CEPI was conceived in 2015 and formally launched in 2017 at the World Economic Forum (WEF) in Davos, Switzerland. It was co-founded and co-funded with US$460 ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Nucleoside-modified Messenger RNA
A nucleoside-modified messenger RNA (modRNA) is a synthetic messenger RNA (mRNA) in which some nucleosides are replaced by other naturally modified nucleosides or by synthetic nucleoside analogues. modRNA is used to induce the production of a desired protein in certain cells. An important application is the development of mRNA vaccines, of which the first authorized were COVID-19 vaccines (such as Comirnaty and Spikevax). Background mRNA is produced by synthesising a ribonucleic acid (RNA) strand from nucleotide building blocks according to a deoxyribonucleic acid (DNA) template, a process that is called transcription. When the building blocks provided to the RNA polymerase include non-standard nucleosides such as pseudouridine — instead of the standard adenosine, cytidine, guanosine, and uridine nucleosides — the resulting mRNA is described as nucleoside-modified. Production of protein begins with assembly of ribosomes on the mRNA, the latter then serving as a blueprint ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
MRNA Vaccine
An mRNA vaccine is a type of vaccine that uses a copy of a molecule called messenger RNA (mRNA) to produce an immune response. The vaccine delivers molecules of antigen-encoding mRNA into immune cells, which use the designed mRNA as a blueprint to build foreign protein that would normally be produced by a pathogen (such as a virus) or by a cancer cell. These protein molecules stimulate an adaptive immune response that teaches the body to identify and destroy the corresponding pathogen or cancer cells. The mRNA is delivered by a co-formulation of the RNA encapsulated in lipid nanoparticles that protect the RNA strands and help their absorption into the cells. Reactogenicity, the tendency of a vaccine to produce adverse reactions, is similar to that of conventional non-RNA vaccines. People susceptible to an autoimmune response may have an adverse reaction to messenger RNA vaccines. The advantages of mRNA vaccines over traditional vaccines are ease of design, speed and lower c ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
GlaxoSmithKline
GSK plc, formerly GlaxoSmithKline plc, is a British multinational pharmaceutical and biotechnology company with global headquarters in London, England. Established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. GSK is the tenth largest pharmaceutical company and #294 on the 2022 ''Fortune'' Global 500, ranked behind other pharmaceutical companies China Resources, Sinopharm, Johnson & Johnson, Pfizer, Roche, AbbVie, Novartis, Bayer, and Merck. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. , it had a market capitalisation of £70 billion, the eighth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange. The company developed the first malaria vaccine, RTS,S, which it said in 2014 it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization's List of Essential Medicines, such ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
BioNTech
BioNTech SE ( ; or short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer. The company has developed an mRNA-based human therapeutic for intravenous administration to bring individualized mRNA-based cancer immunotherapy to clinical trials and to establish its own manufacturing process. In 2020, BioNTech, partnering with Pfizer for testing and logistics, developed the RNA vaccine BNT162b2 for preventing COVID-19 infections, which at the time offered a 91% efficacy in preventing ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Hans-Georg Rammensee
Hans-Georg Rammensee (born 12 April 1953) is a German immunologist and cancer researcher. He has been Chair Professor and Head of the Department of Immunology at the University of Tübingen since 1996. Rammensee has contributed essentially to the research fields of MHC biology and tumor immunology and to the development of cancer immunotherapies. Life Rammensee studied Biology at the University of Tübingen and worked as a PhD student at the Max Planck Institute for Biology in Tübingen. After gaining his doctorate in 1982 he initially worked as a post-doctoral research fellow at Scripps Research Institute, La Jolla, USA. In 1985 he moved as a scientific member to the Basel Institute for Immunology, Basel, Switzerland. Two years later Rammensee returned to Max Planck Institute for Biology as a group leader at the department of immunogenetics. 1993 he became head of department at the Tumor-Virus-Immunology Section of the German Cancer Research Center, Heidelberg, Germany. The sa ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
International AIDS Vaccine Initiative
The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS. IAVI researches and develops vaccine candidates, conducts policy analyses, serves as an advocate for the HIV prevention field and engages communities in the trial process and AIDS vaccine education. The organization takes a comprehensive approach to HIV and AIDS that supports existing HIV prevention and treatment programs while emphasizing the need for new AIDS prevention tools. It also works to ensure that future vaccines will be accessible to all who need them.Berkley, Seth. (2006). Ending an epidemic: the International AIDS Vaccine Initiative pioneers a public-private partnership. ''Innovations'', Vol. 1, No. 1. 52–66. History In 1994, the Rockefeller Foundation convened an international meeting of AIDS researchers, vaccinologists, public health officials, and representatives from phil ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
Cabinet Of Germany
The Federal Cabinet or Federal Government (german: link=no, Bundeskabinett or ') is the chief executive body of the Federal Republic of Germany. It consists of the Federal Chancellor and cabinet ministers. The fundamentals of the cabinet's organisation as well as the method of its election and appointment as well as the procedure for its dismissal are set down in articles 62 through 69 of the Basic Law for the Federal Republic of Germany (''Grundgesetz''). In contrast to the system under the Weimar Republic, the Bundestag may only dismiss the Chancellor with a constructive vote of no confidence (electing a new Chancellor at the same time) and can thereby only choose to dismiss the Chancellor with their entire cabinet and not simply individual ministers. These procedures and mechanisms were put in place by the authors of the Basic Law to both prevent another dictatorship and to ensure that there will not be a political vacuum left by the removal of Chancellor through a vote o ... [...More Info...] [...Related Items...] OR: [Wikipedia] [Google] [Baidu] |
gründungsfoto.jpg "Click for more on -> Ingmar Hoerr")
